Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD 301 and 302 data shows value of targeting avb6-integrin

Friday, March 15, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has reported positive updates regarding its clinical programs, including the dosing of the first patient in the Phase 1/2a study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. These developments highlight the potential value of targeting avb6-integrin in their research.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive clinical updates across multiple programs.
  • IND approval from US FDA to initiate Phase I study.
  • First patient dosed in Phase 1/2a clinical study.

Full Press Release Details

• Announcements
• March 15, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• June 20, 2024
• Announcements
• December 19, 2024
• Announcements
• November 26, 2021
• Announcements
• October 19, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What are RAD 301 and 302 studies about?

RAD 301 and 302 studies focus on targeting avb6-integrin in clinical trials.

What recent updates has Radiopharm Theranostics provided?

Radiopharm Theranostics reported positive clinical updates and FDA approval for new studies.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate being studied in Phase 1/2a clinical trials.

Has Radiopharm received any FDA approvals recently?

Yes, Radiopharm received IND approval from the US FDA for a Phase I study targeting B7H3.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a B7H3 FDA approval
Last updated: Mar 15, 2024